Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 3, 2010, Pages 1125-1131

  Krakauer, Teresa ^a   Buckley, Marilyn ^a   Issaq, Haleem J ^b   Fox, Stephen D ^b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RAPAMYCIN; STAPHYLOCOCCUS ENTEROTOXIN B; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SEPTIC SHOCK; STIMULATION; T LYMPHOCYTE; WEIGHT REDUCTION;

ANIMALS; ANTI-BACTERIAL AGENTS; CYTOKINES; ENTEROTOXINS; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C3H; SHOCK, SEPTIC; SIROLIMUS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 77149139107     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01015-09     Document Type: Article

References (56)

1. Arad, G., R. Levy, D. Hillman, and R. Kaempfer. 2000. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat. Med. 6:414-421.
2. + regulatory T cells. Blood 105: 4743-4748.
3. Bell, A., L. Grunder, and A. Sorisky. 2000. Rapamycin inhibits human adipocyte differentiation in primary culture. Obes. Res. 8:249-254.
4. Bergdoll, M. S. 1988. Monkey feeding test for staphylococcal enterotoxin. Methods Enzymol. 165:324-333.
5. Biecker, E., A. DeGottardi, M. Neef, M. Unternahrer, V. Schneider, M. Ledermann, H. Sagesser, S. Shaw, and R. Reichen. 2005. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J. Pharmacol. Exp. Ther. 313:952-961.
6. Blank, C., A. Luz, S. Bendigs, A. Erdmann, H. Wagner, and K. Heeg. 1997. Superantigen and endotoxin synergize in the induction of lethal shock. Eur. J. Immunol. 27:825-833.
7. Blazar, B., R. P. A. Taylor, S. N. Sehgal, and D. A. Vallera. 1994. Rapamycin, a potent inhibitor of T cell function, prevents graft rejection in murine recipients of allogeneic T-cell depended donor marrow. Blood 83:600-609.
8. Chesney, P. J., J. P. Davis, W. K. Purday, P. J. Wand, and R. W. Chesney. 1981. Clinical manifestations of toxic shock syndrome. JAMA 246:741-748.
9. Choi, Y., B. Kotzin, L. Hernon, J. Callahan, P. Marrack, and J. Kappler. 1989. Interaction of Staphyloccocus aureus toxin "superantigens" with human T cells. Proc. Natl. Acad. Sci. U. S. A. 86:8941-8945.
10. + regulatory T cells. Blood 107:1018-1023.
11. Darenberg, J., B. Soderquist, B. H. Normark, and A. A. Norrby-Tegland. 2004. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigen: implications for therapy of toxic shock syndrome. Clin. Infect. Dis. 38:836-842.
12. + progenitor-derived dendritic cells. J. Biomed. Mater. Res. A 85:983-992.
13. Erbay, E., and J. Chen. 2001. The mammalian target of rapamycin regulates C2C12 myogenesis via a kinase-independent mechanism. J. Biol. Chem. 276:36079-36082.
14. Flechner, S. M. 2009. Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors. Transplantation 87:S1-S6.
15. Fleischer, B., H. Schrezenmeier, and P. Conradt. 1989. T lymphocyte activation by staphylococcal enterotoxins: role of class II molecules and T cell surface structures. Cell. Immunol. 120:92-101.
16. Frost, P., Y. Shi, B. Hoang, J. Gera, and A. Lichtenstein. 2009. Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin. Mol. Cancer Ther. 8:83-93.
17. Gomez-Cambronero, J. 2003. Rapamycin inhibits GM-CSF-induced neutrophil migration. FEBS Lett. 550:94-100.
18. Granville, C. A., N. Warfel, J. Tsurutani, and M. C. Hollander, et. al. 2007. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogeninduced murine lung tumors. Clin. Cancer Res. 13:2281-2289.
19. + cells. J. Exp. Med. 205: 565-574.
20. Heitman, J., N. R. Movva, and M. N. Hall. 1991. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253:905-909.
21. Holmberg, S. D., and P. A. Blake. 1984. Staphylococcal food poisoning in the United States. New facts and old misconceptions. JAMA 251:487-489.
22. Huzella, L. M., M. J. Buckley, D. A. Alves, B. G. Stiles, and T. Krakauer. 2009. Central roles for IL-2 and MCP-1 following intranasal exposure to SEB: a new mouse model. Res. Vet. Sci. 86:241-247.
23. Koehl, G. E., J. Andrassy, M. Guba, S. Richter, A. Kroemer, M. N. Scherer, M. Steinbauer, C. Graeb, H. J. Schlitt, K.-W. Jauch, and E. K. Geissler. 2004. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77:1319-1326.
24. Kotzin, B. L., D. Y. M. Leung, J. Kappler, and P. A. Marrack. 1993. Superantigens and their potential role in human disease. Adv. Immunol. 54:99-166.
25. Krakauer, T. 1995. Inhibition of toxic shock syndrome toxin-induced cytokine production and T cell activation by interleukin 10, interleukin 4, and dexamethasone. J. Infect. Dis. 172:988-992.
26. Krakauer, T. 1999. The induction of CC chemokines in human peripheral blood mononuclear cells by staphylococcal exotoxins and its prevention by pentoxifylline. J. Leukoc. Biol. 66:158-164.
27. Krakauer, T., and M. Buckley. 2006. Dexamethasone attenuates staphylococcal enterotoxin B-induced hypothermic response and protects mice from superantigen-induced toxic shock. Antimicrob. Agents Chemother. 50:391-395.
28. Madsen, J. M. 2001. Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents. Clin. Lab. Med. 21:593-605.
29. Marrack, P., and J. Kappler. 1990. The staphylococcal enterotoxins and their relatives. Science 248:705-709.
30. McCormick, J. K., J. M. Yarwood, and P. M. Schlievert. 2001. Toxic shock syndrome and bacterial superantigens: an update. Annu. Rev. Microbiol. 55:77-104.
31. Mehrad, B., M. D. Burdick, and R. M. Strieter. 2009. Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int. J. Biochem. Cell Biol. 41:1708-1718.
32. Meikle, L., K. Pollizzi, A. Egnor, I. Kramvis, H. Lane, M. Sahin, and D. J. Kwiatkowski. 2008. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J. Neurosci. 28: 5422-5432.
33. Miethke, T., C. Wahl, K. Heeg, B. Echtenacher, P. H. Krammer, and H. Wagner. 1992. T cell-mediated lethal shock triggered in mice by the superantigen SEB: critical role of TNF. J. Exp. Med. 175:91-98.
34. Mita, M. M., A. Mita, and E. K. Rowinsky. 2003. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol. Ther. 2:S169-S177.
35. Mollick, J. A., M. Chintagumpala, R. G. Cook, and R. R. Rich. 1991. Staphylococcal exotoxin activation of T cells. Role of exotoxin-MHC class II binding affinity and class II isotype. J. Immunol. 146:463-468.
36. Mori, H., K. Inoki, K. Masutani, Y. Wakabayashi, K. Komai, R. Nakagawa, K. L. Guan, and A. Yoshimura. 2009. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem. Biophy. Res. Commun. 384:471-475.
37. Nagaki, M., Y. Muto, H. Ohnishi, S. Yasuda, K. Sano, T. Naito, T. Maeda, T. Yamada, and H. Moriwaki. 1994. Hepatic injury and lethal shock in galactosamine-sensitized mice induced by the superantigen staphylococcal enterotoxin B. Gastroenterology 106:450-458.
38. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
39. Proft, T., and J. D. Fraser. 2003. Bacterial superantigens. Clin. Exp. Immunol. 133:299-306.
40. Roy, C. J., K. L. Warfield, B. C. Welcher, R. F. Gonzales, T. Larsen, J. Hanson, C. S. David, T. Krakauer, and S. Bavari. 2005. Human leukocyte antigen-DQ8 transgenic mice: a model to examine the toxicity of aerosolized staphylococcal enterotoxin B. Infect. Immun. 73:2452-2460.
41. Saunders, R. N., M. S. Metcalfe, and M. L. Nicholson. 2001. Rapamycin in transplantation: a review of the evidence. Kidney Int. 59:3-16.
42. Schlievert, P. M. 1993. Role of superantigens in human disease. J. Infect. Dis. 167:997-1002.
43. Scholl, P., A. Diez, W. Mourad, J. Parsonnet, R. S. Geha, and T. Chatila. 1989. Toxic shock syndrome toxin-1 binds to major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. U. S. A. 86:4210-4214.
44. Sehgal, S. N. 2003. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant. Proc. 35:7S-14S.
45. Stevens, D. L. 1996. The toxic shock syndromes. Infect. Dis. Clin. North Am. 10:727-746.
46. Stiles, B. G., S. Bavari, T. Krakauer, and R. G. Ulrich. 1993. Toxicity of staphylococcal enterotoxins potentiated by lipopolysaccharide: major histocompatibility complex class II molecule dependency and cytokine release. Infect. Immun. 61:5333-5338.
47. +regulatory T cells cultured with rapamycin. J. Immunol. 178:320-329.
48. Takano, A., I. Usui, T. Haruta, J. Kawahara, T. Uno, M. Iwata, and M. Kobayashi. 2001. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol. Cell. Biol. 21:5050-5062.
49. Thomson, A. W., H. R. Turnquist, and G. Raimondi. 2009. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9:324-337.
50. Thomson PDR. 2005. Physicians' desk reference, 59th ed., p. 3395-3402. Thomson PDR, Montvale, NJ.
51. Tremblay, F., A. Gagnon, A. Veilleux, A. Sorisky, and A. Marette. 2005. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology 146:1328-1337.
52. Visvanathan, K., A. Charles, J. Bannan, P. Pugach, K. Kashfi, and J. B. Zabriskie. 2001. Inhibition of bacterial superantigens by peptides and antibodies. Infect. Immun. 69:875-884.
53. Wieneke, A., D. Roberts, and R. J. Gilbert. 1993. Staphylococcal food poisoning in the United Kingdom, 1969-1990. Epidemiol. Infect. 110:519-531.
54. KIP1 expression. Blood 101:1439-1445.
55. Wullschleger, S., R. Loewith, and M. N. Hall. 2006. TOR signaling in growth and metabolism. Cell 124:471-484.
56. Yeung, R. S., J. M. Penninger, T. Kundig, W. Khoo, P. S. Ohashi, G. Kroemer, and T. W. Mak. 1996. Human CD4 and human major histocompatibility complex class II (DQ6) transgenic mice: supersensitivity to superantigen-induced septic shock. Eur. J. Immunol. 26:1074-1082.